- Home
- »
- Medical Devices
- »
-
Renal Denervation Catheter Market Size Report, 2026-2033GVR Report cover
Renal Denervation Catheter Market (2026 - 2033)
Size, Share & Trends Analysis Report By Product (Radiofrequency Ablation Catheters, Ultrasound Ablation Catheters), By End-use (Hospital, Others), By Region (North America, Asia Pacific, Europe), And Segment Forecasts
Market Size, 2025
$84.9MMarket Estimate, 2026
$109.4MMarket Forecast, 2033
$454.0MCAGR, 2026–2033
22.5%Renal Denervation Catheter Market Summary
The global renal denervation catheter market size was valued at USD 84.9 million in 2025 and is projected to grow from USD 109.4 million in 2026 to USD 454.0 million by 2033, at a CAGR of 22.5% from 2026 to 2033. Europe dominated the global market, accounting for the largest revenue share of 37.6% in 2025. This growth is primarily driven by the increasing global burden of hypertension, particularly treatment-resistant hypertension, which affects a significant proportion of patients who do not respond adequately to pharmacological therapy.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,Download Free Sample Report
Key Market Trends & Insights
- By product: Radiofrequency (RF) ablation catheters segment led the market with a 75.5% revenue share in 2025.
- By end-use: Hospitals segment led the market, accounting for 84.0% of revenue in 2025.
Regional Highlights
- Largest regional market: Europe (37.6% revenue share, 2025)
- Fastest growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The renal denervation catheter market in Germany held the largest share in the Europe region in 2025.
Market Size & Forecast
- Market size in 2025: USD 84.9 Million
- Estimated market size in 2026: USD 109.4 Million
- Projected market size by 2033: USD 454.0 Million
- CAGR (2026-2033): 22.5%
Prism AI by Grand View Research Free to tryAsk a question about the renal denervation catheter marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →
As a minimally invasive procedure, renal denervation (RDN) offers a promising alternative for patients seeking long-term blood pressure control with fewer medications. According to the NIH, hypertension is a critical public health issue and a leading cause of cardiovascular disease, morbidity, and premature mortality worldwide. About 1.13 billion people - one in six globally - are affected by high blood pressure, which is projected to increase to 1.5 billion by 2025.
To learn more about this report,Download Free Sample Report
The rising global prevalence of hypertension is a significant factor fueling the growth of the renal denervation catheter market. Hypertension remains one of the most significant modifiable risk factors for cardiovascular disease, stroke, and kidney failure, and its incidence continues to escalate due to factors such as aging populations, unhealthy lifestyles, obesity, high salt intake, and increasing levels of stress. According to the WHO, as of March 2023, approximately 1.28 billion adults aged 30 to 79 years are affected by hypertension, with two-thirds of them living in low- and middle-income countries. Particularly concerning the subset of this population is those with resistant hypertension-patients who fail to achieve target blood pressure levels despite using three or more antihypertensive medications, including a diuretic. This group represents a key renal denervation therapy target population.
As awareness of the limitations of pharmacologic treatments grows and the demand for more effective, longer-lasting interventions increases, renal denervation is gaining attention as a minimally invasive option to reduce sympathetic nerve activity and achieve sustained blood pressure control. The increasing clinical and real-world evidence supporting RDN’s efficacy and safety in lowering blood pressure, especially in resistant hypertension, is driving its acceptance among physicians and patients, significantly contributing to the expansion of the renal denervation catheter market.
“Current control rates for hypertension are dismal, and this technology offers a new option for many patients with resistant or difficult-to-control hypertension. Ultrasound renal denervation has been proven safe and effective in rigorous studies. When lifestyle changes and medications are not enough, ultrasound renal denervation holds great promise as an adjunctive therapy to help patients reach their goal BP.” - Naomi D.L. Fisher, MD, director of hypertension services and the hypertension specialty clinic at Brigham and Women’s Hospital.
To learn more about this report,Download Free Sample Report
The growing awareness about hypertension management is expected to drive market growth in the forecast years. Industry players, industry stakeholders, healthcare organizations, and government agencies are actively launching initiatives to educate the public on the importance of regular blood pressure monitoring and early intervention. For instance,
-
World Hypertension Day was observed on May 17, 2025, with the theme “Measure Your Blood Pressure Accurately, Control It, Live Longer!”. This global campaign emphasized the critical role of accurate blood pressure measurement, timely diagnosis, and effective treatment in preventing hypertension-related complications.
-
In addition, in February 2025, the American Heart Association, with support from Providence, launched the “Love Your Heart. Lower the Pressure.” campaign. This initiative encourages individuals to “know their numbers” and collaborate with healthcare providers to manage their blood pressure and lower their risk of cardiovascular diseases, including heart attacks and strokes.
"At Providence, we are deeply committed to advancing health equity and addressing the critical health disparities that impact our communities. By supporting the American Heart Association with this hypertension awareness campaign, we aim to equip communities with the knowledge and resources they need to take control of their heart health. This initiative is not just about raising awareness-it's about creating tangible change and ensuring that everyone, regardless of their background, has access to the care and support necessary to lead a healthy life,” - Whitney Haggerson, Vice President of Health Equity and Medicaid, Providence.
Some of the recently launched campaigns for hypertension awareness
Organization
Campaign Name
Date of Launch
Aim/Goal
Indian Stroke Association (ISA)
Indian Red Cross Society
Rotary Club of Guntur
Check BP - Stop Stroke
April 2025
To raise awareness about the importance of monitoring blood pressure, to prevent major health issues like brain stroke, heart attack and kidney failures.
The Association of Physicians of India (API)
Glenmark Pharmaceuticals
Take charge at 18 - BP Screening Day
September 2024
Emphasizes the critical importance of early blood pressure monitoring beginning at age 18.
Source: Grand View Research Analysis
The increasing number of clinical trials focused on renal denervation catheters is a key driver of market growth. These trials are essential for validating the efficacy, safety, and long-term benefits of RDN as a treatment for resistant and uncontrolled hypertension. The growing body of positive clinical evidence enhances physician confidence, encourages guideline revisions, and prompts regulatory approvals in major markets. Moreover, ongoing multicenter and real-world studies are expanding the understanding of RDNs’ therapeutic scope, including their potential applications in heart failure, chronic kidney disease, and atrial fibrillation management.
Study Title
Conditions
Interventions
Sponsor
Enrollment
Primary Completion Date
REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /
Uncontrolled Stage 2 Hypertension
DEVICE: Renal denervation
SoniVie Inc.
25
2025-12
Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation
Atrial Fibrillation
DEVICE: renal denervation|DEVICE: Catheter ablation
Vivek Reddy
160
2/26/2025
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation Vs Control in Redo Ablation Patients
Paroxysmal Atrial Fibrillation|Persistent Atrial Fibrillation
DEVICE: Renal Denervation|DEVICE: Catheter Ablation
Vivek Reddy
250
2027-12
Source: ClinicalTrials.Gov, Grand View Research Analysis
Market Dynamics
The renal denervation catheter market is growing, driven by the rising prevalence of uncontrolled and treatment-resistant hypertension and the increasing demand for minimally invasive device-based treatment options. Growing clinical evidence demonstrating the safety, efficacy, and long-term blood pressure-lowering effects of renal denervation procedures is accelerating the adoption of renal denervation catheters among healthcare providers. Regulatory approvals of advanced renal denervation catheter technologies, expanding reimbursement coverage, and their inclusion in hypertension management guidelines are further supporting market expansion. In addition, continuous technological advancements, including enhanced radiofrequency and ultrasound-enabled catheter designs, are improving procedural precision, treatment consistency, and clinical outcomes, contributing to increased utilization of renal denervation catheters worldwide.
The rising prevalence of hypertension is a major driver of the renal denervation catheter market. A significant number of patients continue to experience uncontrolled blood pressure despite treatment with multiple antihypertensive medications, creating a growing demand for alternative therapeutic options. Renal denervation catheters play a critical role in addressing this need by enabling minimally invasive procedures that disrupt overactive renal sympathetic nerves associated with hypertension. The expanding population of patients with resistant or inadequately controlled hypertension is increasing the adoption of these specialized catheters in clinical practice. Rising awareness among healthcare providers of renal denervation's benefits, coupled with concerns about medication nonadherence, side effects, and the long-term treatment burden, is driving demand for catheter-based interventions.
• According to the data published by the WHO in 2025, an estimated 1.4 billion adults aged 30-79 years worldwide were living with hypertension in 2024, representing approximately 33% of the population in this age group. Nearly two-thirds (around 66%) of affected individuals reside in low- and middle-income countries, highlighting a significant global health disparity. Despite its high prevalence, about 600 million individuals (44%) remain unaware of their condition, while approximately 630 million (44%) are diagnosed and receiving treatment. However, only around 320 million (23%) have their blood pressure effectively under control, indicating a substantial gap in disease management. This widespread lack of awareness and control underscores hypertension’s role as a major contributor to premature mortality worldwide.
The high cost of renal denervation catheters and associated procedural equipment remains a significant restraint for the renal denervation catheter market. These catheters are designed with advanced technologies, such as radiofrequency or ultrasound energy delivery systems, which contribute to higher acquisition costs than those of conventional interventional devices. In addition, the procedure requires specialized infrastructure, imaging guidance, and skilled physicians, thereby increasing treatment costs. Reimbursement frameworks for renal denervation procedures are still developing in several countries, limiting the adoption of renal denervation catheters across healthcare facilities. Payers frequently seek strong long-term clinical and cost-effectiveness data before expanding coverage, which can delay market penetration. The financial burden is particularly evident in emerging economies, where budget constraints and high out-of-pocket healthcare spending restrict patient access.
Continuous innovation in renal denervation catheters presents a significant growth opportunity for the market. Manufacturers are developing next-generation catheters incorporating advanced radiofrequency (RF), ultrasound, and other energy-delivery technologies to enhance procedural precision, treatment effectiveness, and safety. Improvements in catheter design, including multi-electrode configurations, optimized energy distribution, and enhanced navigability within renal arteries, are helping to improve nerve targeting and procedural consistency. These advancements can reduce procedure time, simplify physician workflows, and increase operator confidence, supporting wider adoption in interventional cardiology and hypertension treatment centers. Ongoing clinical studies continue to demonstrate the long-term blood pressure-lowering benefits of catheter-based renal denervation, encouraging greater acceptance among physicians and healthcare systems.
• In September 2025, Medtronic Japan announced that it had obtained regulatory approval in Japan for the Symplicity Spyral Renal Denervation System, a catheter-based therapy designed to treat treatment-resistant hypertension. The approval enables the company to proceed with reimbursement-related processes toward commercial adoption in Japan. The system utilizes a multi-electrode renal denervation catheter to deliver radiofrequency energy to renal nerves, providing an adjunctive treatment option for patients whose blood pressure remains uncontrolled despite medication and lifestyle interventions.
Market Concentration & Characteristics
The renal denervation catheter industry is in a high-growth stage, driven by the increasing global burden of hypertension-particularly treatment-resistant cases-along with growing clinical evidence supporting the safety and efficacy of renal denervation procedures.
The industry is highly innovative, marked by continuous technological advancements and evolving therapeutic approaches. Notable innovations include multi-electrode catheters, automated energy delivery, and real-time temperature and impedance monitoring, all of which enhance procedural consistency and outcomes. Medtronic (Symplicity Spyral) and Recor Medical (Paradise Ultrasound RDN System) lead innovation through stringent clinical trials and regulatory engagement.
To learn more about this report,Download Free Sample Report
The industry has witnessed moderate but strategically significant mergers and acquisitions (M&A) activity in recent years. Although not characterized by a high volume of transactions, the deals that have occurred reflect focused consolidation, strategic entry, and technology acquisition by major medtech companies. As the market matures and clinical evidence supporting renal denervation becomes more potent, the level of M&A activity is expected to rise, particularly as large medtech players seek to diversify their hypertension treatment offerings and capitalize on emerging therapeutic segments. For instance, in March 2025, Boston Scientific Corporation entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company. SoniVie has developed the TIVUS Intravascular Ultrasound System, an investigational technology designed to denervate nerves surrounding blood vessels to address various hypertensive conditions, including renal artery denervation for hypertension.
Regulations play a critical and developing role in shaping the growth of the renal denervation catheter market. RDN systems are subject to stringent safety and efficacy assessments by regulatory authorities such as the U.S. FDA, European Medicines Agency (EMA), Japan’s PMDA, and China’s NMPA. Approval delays in some regions, particularly those with more conservative evidence thresholds, may limit market access temporarily. However, the increasing alignment between clinical trial outcomes and regulatory expectations drives a more supportive environment for innovation, commercialization, and global expansion of renal denervation technologies.
Product expansion in the industry is a key growth driver, as manufacturers diversify and upgrade their product offerings to meet evolving clinical needs. Companies are launching next-generation systems incorporating advanced features such as multi-electrode configurations, real-time imaging capabilities, and dual-access compatibility to enhance procedural precision and safety. These innovations improve treatment efficacy, reduce procedure time, and broaden the applicability of renal denervation in complex patient populations, including those with resistant hypertension or chronic kidney disease.
Regional expansion is playing a pivotal role in driving the global growth of the renal denervation catheter industry, as manufacturers and stakeholders actively seek to penetrate emerging and underdeveloped healthcare markets. While early adoption was primarily concentrated in Europe, where CE-marked RDN systems have been in clinical use for several years, recent U.S. FDA approvals have opened one of the largest potential markets globally.
Analyst Perspective
The renal denervation catheter market is witnessing growth, driven by the rising global prevalence of uncontrolled and treatment-resistant hypertension, increasing cardiovascular risk burden, and expanding clinical acceptance of device-based hypertension therapies. Market participants are increasingly focusing on next-generation renal denervation technologies, including radiofrequency, ultrasound-based, and multi-electrode catheter systems, to improve procedural efficacy, safety, and long-term blood pressure control outcomes. The shift from conservative pharmacological management toward minimally invasive interventional hypertension treatment is expected to accelerate procedural adoption across Cath labs and hypertension specialty centers. In addition, growing clinical evidence, guideline endorsements from key cardiovascular societies, and ongoing regulatory approvals in major markets such as the U.S. and Europe are supporting broader physician adoption.
Product Insights
Based on product, the Radiofrequency (RF) ablation catheters segment led the market with a 75.5% revenue share in 2025, driven by its established clinical efficacy, procedural precision, and widespread adoption in clinical trials and commercial settings. For instance, in November 2023, the U.S. FDA approved Medtronic's Symplicity Spyral RDN system. This minimally invasive device utilizes radiofrequency energy to target overactive renal nerves contributing to high blood pressure. Furthermore, in January 2025, the Centers for Medicare & Medicaid Services (CMS) initiated a national coverage analysis (NCA) for renal denervation procedures. This was prompted by Medtronic's request to support Medicare coverage for the Symplicity Spyral system to improve access for hypertensive patients. Furthermore, the familiarity of healthcare providers with RF-based systems, streamlined procedural workflows, and ongoing product enhancements continues to support the segment's dominance. As regulatory approvals and reimbursement support increase globally, the RF ablation catheter segment is expected to maintain a strong lead in the market.
Ultrasound ablation catheters are expected to grow at the fastest CAGR over the forecast period due to its innovative, non-contact energy delivery mechanism. This mechanism allows for circumferential ablation of renal nerves with greater consistency and reduced procedural variability. Multiple clinical studies have validated the efficacy of ultrasound-based systems. For instance, the RADIANCE-HTN SOLO trial, published in October 2023, evaluated the ReCor Medical Paradise System in patients with mild to moderate hypertension. The results showed that renal denervation using the Paradise endovascular ultrasound system led to a significantly greater reduction in systolic and diastolic blood pressure at two months post-procedure compared to the sham control group. These positive findings support the rapid clinical growth of the ultrasound ablation catheter segment.
End Use Insights
Based on end-use, the hospitals segment led the market, accounting for 84.0% of revenue in 2025, driven by the widespread adoption of RDN procedures in hospital settings. Hospitals have the necessary infrastructure and specialist expertise to perform these minimally invasive interventions. For instance, in 2024, Houston Methodist became the first hospital in Houston to perform the renal denervation procedure, highlighting its role in adopting this non-pharmacologic treatment for hypertension. Such early clinical adoption by healthcare institutions continues to support the dominance of hospitals in the market.Moreover, manufacturers are collaborating with hospitals to train about renal denervation technologies and expand clinical adoption. For instance, in April 2025, Medtronic partnered with KIMS-Sunshine Hospital to establish a specialized renal denervation center.
“This is an important milestone and hopefully the beginning of a new era marked by more innovative, durable and diverse treatment options for a condition that affects so many and contributes to so much of the global burden of disease. Prescription drugs are effective, widely available and affordable, but they don't work for everyone, and adherence is an enormous problem." - Dr. Alpesh Shah, director of Coronary Interventions at Houston Methodist.
To learn more about this report,Download Free Sample Report
Others are expected to grow at the fastest CAGR over the forecast period. The other segment of the renal denervation catheter market encompasses a variety of healthcare settings, including ambulatory surgery centers, specialty clinics, research centers, and academic institutions, among others. This segment is experiencing growth driven by the rising number of clinical studies and research initiatives to develop and evaluate RDN technologies. Several academic centers have already adopted these procedures. For instance, in July 2022, the Kaplan Medical Center in Israel-affiliated with the Hebrew University Medical School-treated its first patient using Tivus therapeutic intravascular ultrasound technology.
Regional Insights
Europe dominated the renal denervation catheter market, accounting for the largest revenue share of 37.6% in 2025. This dominance is primarily driven by the early adoption of renal denervation technologies, favorable regulatory environment, and strong clinical research infrastructure across the region. European countries such as Germany, France, and the UK have been at the forefront of conducting pivotal RDN clinical trials, including the SPYRAL HTN and RADIANCE-HTN series, which have significantly contributed to the evidence base for RDN’s efficacy and safety.
To learn more about this report,Download Free Sample Report
The European Society of Cardiology (ESC), in collaboration with the European Society of Endocrinology (ESE) and the European Stroke Organization (ESO), has recognized catheter-based renal denervation (RDN) as a potential therapy for certain patients with hypertension, as per their latest guidelines.
The recommendations below reflect the growing clinical acceptance of RDN as a complementary therapy for managing difficult-to-control hypertension, while emphasizing patient preference and individualized risk-benefit evaluation.
Recommendations
Class
Level
To reduce BP, and if performed at a medium-to-high volume center, catheter-based renal denervation may be considered for resistant hypertension patients who have BP that is uncontrolled despite a three BP-lowering drug combination (including a thiazide or thiazide-like diuretic), and who express a preference to undergo renal denervation after a shared risk-benefit discussion and multidisciplinary assessment.
IIb
B
To reduce BP, and if performed at a medium-to-high volume center, catheter-based renal denervation may be considered for patients with both increased CVD risk and uncontrolled hypertension on fewer than three drugs, if they express a preference to undergo renal denervation after a shared risk-benefit discussion and multidisciplinary assessment.
IIb
A
Due to a lack of adequately powered outcomes trials demonstrating its safety and CVD benefit to renal denervation is not recommended as a first-line BP-lowering intervention for hypertension.
III
C
Source: European Society of Cardiology, 2024
The renal denervation catheter market in the UK is expected to grow significantly in the forecast period. The rising prevalence of hypertension and resistant hypertension is a significant driver of the renal denervation catheter market in the UK. Hypertension affects nearly 30% of adults in the country, and a considerable proportion of these individuals struggle to achieve adequate blood pressure control despite the use of multiple antihypertensive medications. This condition, known as resistant hypertension, poses serious cardiovascular risks and increases the healthcare burden. As per the NHS update in September 2024, 32% of adults have high blood pressure. In the Southeast, 70 per cent of people with high blood pressure have their condition under control, but it’s estimated there are around 400,000 people with uncontrolled high blood pressure - many of whom do not know that they have high blood pressure.
The renal denervation catheter market in Germany held the largest share in the Europe region in 2025. Germany has a large and aging population, with a high prevalence of hypertension, particularly resistant hypertension-a condition where blood pressure remains uncontrolled despite the use of three or more antihypertensive medications. This growing patient pool strongly demands alternative, device-based therapies like renal denervation. Based on the WHO 2023 Hypertension Profile for Germany, hypertension remains a significant public health challenge, with an estimated 19.8 million adults aged 30-79 years affected.
Product launches in Germany significantly accelerate the growth of the renal denervation catheter market, positioning the country as a strategic hub for adoption and innovation. Germany's healthcare system is among the most advanced in Europe, and it plays a pioneering role in introducing and evaluating novel medical technologies. In October 2021, ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., initiated the commercial launch of its Paradise ultrasound renal denervation system in Europe, with Germany being the first country where the system is available for the treatment of uncontrolled hypertension. The initial commercial procedures were successfully performed at two leading institutions-Heart Center Leipzig and Saarland University Hospital in Homburg/Saar.
"Despite the availability of antihypertensive medications, many patients fail to control their hypertension, a dangerous condition that can lead to heart attack and death. Clinical data from the ACHIEVE, RADIOSOUND, RADIANCE-HTN SOLO, and TRIO trials show that ultrasound renal denervation with the Paradise System can lower blood pressure and is a new treatment option for physicians to help their selected patients. We are pleased to be one of the first hospitals in Europe to offer renal denervation with ultrasound."- Professor Felix Mahfoud, MD, with Saarland University Hospital
North America Renal Denervation Catheter Market Trends
North America renal denervation catheter market is witnessing significant growth, driven by the rising prevalence of treatment-resistant hypertension. The U.S. leads the regional market, supported by the recent FDA approvals of major RDN systems such as Medtronic’s Symplicity Spyral and Recor Medical’s Paradise system. These regulations have catalyzed clinical adoption and spurred investment in RDN technologies.
The renal denervation catheter market in the U.S. held the largest share in North America in 2025.The rising prevalence of hypertension in the U.S. is a significant factor driving the growth of the renal denervation catheter market. According to the CDC, nearly half of U.S. adults have hypertension, and a significant proportion of them struggle to maintain adequate blood pressure control despite taking multiple medications. This growing patient population represents the core target for renal denervation, which offers a non-pharmacologic, minimally invasive solution to long-term blood pressure management. As the burden of hypertension continues to rise-driven by aging demographics, sedentary lifestyles, obesity, and dietary habits- the demand for innovative, device-based interventions like RDN is increasing.
According to CDC update in January 2025:
-
In 2022, high blood pressure was a primary or contributing cause of 685,875 deaths in the U.S.
-
About 1 in 5 deaths related to COVID-19 occurred in people with a history of hypertensive disease.
To learn more about this report,Download Free Sample Report
“There are many patients with hypertension refractory to multiple medications, and with multiple hospitalizations and even prior CV events due to uncontrollable BP. To at least have some hope that we may be able to control their BP better is so gratifying. There are so many patients with BP that is uncontrolled despite the best efforts at lifestyle modification and medications. The approval of a renal denervation device offers clinicians the ability to offer a device-based adjunct to their care that may help them be better controlled.”- Ajay J. Kirtane, MD, SM, director of Columbia Interventional Cardiovascular Care.
The U.S. market is driven by key regulatory and reimbursement achievements between 2023 and 2025. In November 2023, the U.S. FDA approved the first renal denervation systems: Medtronic’s Symplicity Spyral, which uses radiofrequency, and ReCor Medical’s Paradise System, which utilizes ultrasound energy.
To learn more about this report,Download Free Sample Report
Asia Pacific Renal Denervation Catheter Market Trends
The renal denervation catheter market in Asia Pacific is experiencing the fastest growth globally, fueled by the rising prevalence of hypertension, increasing awareness about treatment-resistant cases, and expansion of healthcare access across emerging economies. Countries such as China, India, Japan, South Korea, and Australia are leading the adoption, driven by large hypertensive populations and a growing burden of cardiovascular disease. According to WHO estimates, countries in the region are seeing high rates of uncontrolled hypertension, with treatment adherence remaining a significant challenge. This has created a strong demand for alternative therapies like renal denervation, particularly in patients who are non-compliant or unresponsive to medication.
India renal denervation catheter marketis anticipated to witness significant growth over the forecast period. India has a rapidly increasing prevalence of hypertension. A significant portion of these individuals experience uncontrolled or resistant hypertension, defined as high blood pressure that remains elevated despite treatment with three or more antihypertensive drugs. This clinical gap has led to a growing demand for alternative therapies like RDN, which provides a non-pharmacological intervention for blood pressure control. As per the WHO, cardiovascular diseases, including heart attacks and strokes, are the leading cause of death and illness globally and account for nearly one-third of all deaths in India. Uncontrolled hypertension is a major contributing risk factor for CVD. Among the approximately 220 million people in India affected by high blood pressure, only about 12% have their condition adequately controlled.
Strategic partnerships and training initiatives in India drive the renal denervation catheter market by expanding clinical expertise and procedural adoption. In addition, the launch of advanced technologies like next-generation renal denervation systems is improving treatment outcomes and boosting physician acceptance.
- In April 2025, KIMS‑Sunshine Hospital in Hyderabad has partnered with Medtronic to establish a specialized Renal Denervation Therapy Center to treat patients with resistant or uncontrolled hypertension. As part of the collaboration, Medtronic will provide extensive training programs and workshops for healthcare professionals, ensuring they have the latest expertise in patient selection, procedural techniques, and post‑operation management.
“With the Symplicity blood pressure procedure, we aim to empower healthcare professionals and offer a comprehensive approach to managing uncontrolled hypertension that supports our patient-centered approach to care. The recently announced U.S. FDA approval for the RDN system and an update earlier this year of the European Hypertension Society guidelines highlight the role of RDN as part of the hypertension care pathway. We are excited to offer this therapy to all eligible patients in India. As leaders in cardiovascular therapies, Medtronic remains committed to providing innovative solutions that improve patients’ lives.” - Michael Blackwell, Vice President and Managing Director, Medtronic India.
The renal denervation catheter market in China is growing, due to the high prevalence of hypertension in China, which is among the highest globally. According to the National Center for Cardiovascular Diseases, over 270 million people in China suffer from hypertension, with poor control rates despite widespread availability of pharmacological treatments. This has created an urgent need for alternative treatment options such as RDN.
Furthermore, the Chinese government's focus on healthcare reform and domestic medical innovation has enabled a supportive regulatory environment. The National Medical Products Administration (NMPA) has accelerated approval pathways for innovative Class III devices, including RDN catheters, promoting quicker market access for local and international players. The investment of major global and domestic MedTech companies in strategic collaborations, clinical trials, and product rollouts has boosted market awareness and confidence among healthcare professionals. These drivers are positioning China as a rapidly growing and strategically important market for renal denervation technologies.
Some of the key approvals in China by NMPA
Month & Year
Company
Product Name
Device Type
Regulatory Status
Aug-24
SyMap Medical
msRDN Selective Renal Denervation System
Selective Renal Denervation (Class III device)
Class III Medical Device Approval
May-24
Medtronic
Symplicity Spyral Renal Denervation System
Radio Frequency Renal Ablation System
Approved for marketing
Source: NMPA, GVR, Medtronic
“As the leader in renal denervation, we are looking forward to bringing the Symplicity blood pressure procedure to China, where high blood pressure rates continue to increase. As these rates continue to climb, the need for innovative, alternative treatments is strong. The Symplicity procedure can provide people in China with another potential option when seeking high blood pressure solutions, complementing lifestyle modifications and medication.”- Jason Weidman, senior vice president and president of the Coronary and Renal Denervation business within the Cardiovascular Portfolio at Medtronic.
Middle East & Africa Renal Denervation Catheter Market Trends
The renal denervation catheter market in the Middle East and Africa is witnessing gradual growth, driven by the rising prevalence of hypertension and the increasing need for effective treatment options for resistant cases. Lifestyle-related factors such as high obesity rates, sedentary behavior, and excessive salt intake are fueling the hypertension burden, particularly in Gulf countries like Saudi Arabia, the UAE, and Kuwait. At the same time, growing investments in healthcare infrastructure and the expansion of specialized cardiac care centers are creating favorable conditions for the adoption of advanced interventional therapies like renal denervation. As awareness and infrastructure continue to improve, especially in urban centers, the MEA region is expected to become a promising growth area for renal denervation technologies over the forecast years.
Key Renal Denervation Catheter Company Insights
Key players operating in the renal denervation catheter market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.
Key Renal Denervation Catheter Companies:
The following key companies have been profiled for this study on the renal denervation catheter market.
-
Recor Medical, Inc. (Otsuka Medical Devices Co., Ltd.)
-
Medtronic
-
Boston Scientific Corporation
-
Shanghai Bio-heart Biological Technology Co., Ltd.
-
MicroPort Scientific Corporation
-
EnligHTN, ST. JUDE MEDICAL (Abbott Laboratories)
-
Suzhou Xinmai Medical Technology Co., Ltd.
-
Ablative Solutions, Inc.
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (Recor Medical, Inc. (Otsuka Medical Devices Co., Ltd.), Medtronic, Boston Scientific Corporation, MicroPort Scientific Corporation, EnligHTN, ST. JUDE MEDICAL (Abbott Laboratories))
- Expand clinical evidence through large-scale trials, long-term safety data, and regulatory approvals to strengthen adoption globally.
- Companies invest in technology innovation, physician training, and strategic partnerships to improve procedures, expand market reach, and increase competitiveness.
- Strong clinical evidence and regulatory approvals enhance physician confidence, supporting broader adoption and market leadership in renal denervation.
- Advanced device technologies, extensive distribution networks, and physician training programs provide differentiation and strengthen competitive positioning.
- High dependence on favorable reimbursement policies and regulatory approvals can limit market expansion and commercial adoption.
- Significant investment requirements for clinical trials, physician education, and product development increase operational and financial pressures.
Emerging Players (Shanghai Bio-heart Biological Technology Co., Ltd., Suzhou Xinmai Medical Technology Co., Ltd. (SyMap Medical), Ablative Solutions, Inc.)
- Focus on developing innovative and cost-effective renal denervation technologies to address unmet clinical needs and gain market recognition.
- Companies pursue strategic collaborations, pilot clinical studies, and regional regulatory approvals to accelerate commercialization and expand their customer base.
- Agile development capabilities enable rapid innovation and faster introduction of next-generation renal denervation technologies.
- Focused product portfolios and competitive pricing strategies help attract healthcare providers and gain market share in emerging regions.
- Limited brand recognition and smaller distribution networks restrict market penetration and physician adoption compared with established competitors.
- Constrained financial resources and limited clinical evidence can slow regulatory approvals, product development, and commercial expansion efforts.
Recent Developments
-
In March 2025, Boston Scientific Corporation announced a definitive agreement to acquire SoniVie Ltd., a privately held medical device company. SoniVie has developed the TIVUS Intravascular Ultrasound System, an investigational technology designed to denervate nerves surrounding blood vessels to address various hypertensive conditions, including renal artery denervation (RDN) for hypertension.
-
In January 2025, Medtronic announced that the Centers for Medicare & Medicaid Services (CMS) has initiated a national coverage analysis (NCA) for renal denervation. This process will enable CMS to review and establish a nationwide Medicare coverage policy for renal denervation procedures in patients with hypertension.
Renal Denervation Catheter Market Report Scope
Report Attribute
Details
Market size in 2025
USD 84.9 million
Estimated market size in 2026
USD 109.4 million
Projected market size by 2033
USD 454.0 million
Growth rate
CAGR of 22.5% from 2026 to 2033
Historical data
2021 - 2024
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Product, end-use, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Norway; Denmark; Sweden; Russia; Iceland; Finland; China; Japan; India; South Korea; Australia; Thailand; Singapore; Brazil; Argentina; Saudi Arabia; South Africa; UAE; Kuwait; Israel
Key companies profiled
Recor Medical, Inc. (Otsuka Medical Devices Co., Ltd.), Medtronic, Shanghai Bio-heart Biological Technology Co., Ltd., Boston Scientific Corporation, MicroPort Scientific Corporation, EnligHTN, ST. JUDE MEDICAL (Abbott Laboratories), Suzhou Xinmai Medical Technology Co., Ltd. (SyMap Medical), Ablative Solutions, Inc., among others.
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Renal Denervation Catheter Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2025 to 2033. For this study, Grand View Research has segmented the global renal denervation catheter market report based on product, end use, and region:
To learn more about this report,Download Free Sample Report
-
Product Outlook (Revenue, USD Million, 2025 - 2033)
-
Radiofrequency (RF) Ablation Catheters
-
Ultrasound Ablation Catheters
-
-
End Use Outlook (Revenue, USD Million, 2025 - 2033)
-
Hospitals
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2025 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
South Korea
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The renal denervation catheter market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each renal denervation catheter segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Product
Revenue capture definition
Radiofrequency (RF) Ablation Catheters
This segment tracks global sales of catheters delivering high-frequency electrical currents to disrupt sympathetic renal nerves. Revenue is captured through direct-to-hospital sales and distributor contracts for both single-use disposable catheters and capital equipment generators utilized during minimally invasive hypertension treatments.
Ultrasound Ablation Catheters
Revenue for this category is derived from the commercialization of specialized acoustic-energy devices that emit targeted sound waves to denervate renal arteries. Financial tracking encompasses the procurement of proprietary non-contact or balloon-based ultrasound probes, with recurring service contracts for their dedicated console hardware.
Delivered Customizations
This report has been delivered with the following In-depth customizations
CLIENT REQUEST
CUSTOMIZATION DELIVERED
VALUE ADDS
2025 Market Revenue Baseline and 2026-2035 Forecast Analysis
Detailed estimation of the renal denervation catheter market revenue for 2025, including segmentation by product, end use, and region. The analysis further provides annual revenue forecasts from 2026 to 2035 based on hypertension prevalence trends, procedure adoption rates, clinical guideline updates, reimbursement expansion, competitive pipeline launches, and regulatory approvals across key markets (U.S., Europe, APAC, and Rest of World).
Enables long-term strategic planning, investment prioritization, and market entry timing. Supports identification of high-growth geographies and technology platforms, scenario-based forecasting, and evaluation of commercialization potential in emerging hypertension treatment pathways.
End-user and Care-setting Demand Assessment
Market sizing and utilization analysis across hospitals, cardiology centers, hybrid cath labs, and specialty hypertension clinics, segmented by procedure volume, physician adoption patterns, and referral pathways. Includes adoption curves across developed and emerging markets and impact of guideline-driven treatment expansion beyond drug-resistant hypertension into broader hypertensive populations.
Supports go-to-market planning, channel prioritization, physician targeting strategies, and identification of early adopter centers and high-volume procedure hubs.
Technology & Competitive Landscape Mapping
Detailed assessment of key renal denervation platforms including radiofrequency-based multi-electrode systems, ultrasound-based catheters, and emerging non-thermal approaches. Includes competitive benchmarking of major players, pipeline analysis, clinical trial outcomes, and regulatory milestones across U.S. FDA, CE Mark, and other approvals.
Enables competitive positioning, R&D prioritization, partnership identification, and tracking of technology convergence trends shaping next-generation hypertension intervention devices.
Frequently Asked Questions About This Report
The renal denervation catheter market is driven by the growing burden of treatment-resistant hypertension and technological advancements in catheter design and energy-delivery systems, such as radiofrequency and ultrasound.
The Radiofrequency (RF) ablation catheters segment led with a 75.5% revenue share in 2025, while ultrasound ablation catheters is the fastest-growing segment.
The hospitals segment led with a 84.0% revenue share in 2025, while others are the fastest-growing segment.
Expanding indications beyond resistant hypertension, increasing adoption in emerging markets, favorable reimbursement developments, and continuous innovation in catheter technologies create significant growth opportunities.
The global renal denervation catheter market size was valued at USD 84.9 million in 2025 and is estimated at USD 109.4 million in 2026.
The global renal denervation catheter market is expected to grow at a compound annual growth rate of 22.5% from 2026 to 2033, reaching USD 454.0 million by 2033.
Europe dominated the renal denervation catheter market, accounting for the largest revenue share of 37.6% in 2025.
Some key players operating in the renal denervation catheter market include Recor Medical, Inc. (Otsuka Medical Devices Co., Ltd.), Medtronic, Shanghai Bio-heart Biological Technology Co., Ltd., Boston Scientific Corporation, MicroPort Scientific Corporation, EnligHTN, ST. JUDE MEDICAL (Abbott Laboratories), Suzhou Xinmai Medical Technology Co., Ltd. (SyMap Medical), Ablative Solutions, Inc., among others.
About the Author(s)
Medical Devices Research Team
Healthcare · Medical DevicesThis report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.